Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.

NCT00813397 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2015-05-22

No results posted yet for this study

Summary

This study will examine the performance of SeprasSpray in patients undergoing abdominal surgery (laparoscopic).

Conditions

  • Adhesion Prevention

Interventions

DEVICE

Sepraspray

Max. 10g of Sepraspray

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Genzyme, a Sanofi Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813397 on ClinicalTrials.gov